Health Care [ 4/12 ] | Health Care Equipment & Supplies [ 43/72 ]
NYSE | Common Stock
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
It operates through MedSurg and Cardiovascular segments.
The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.
It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems.
In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions.
Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer.
The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 24, 24 | 0.62 Increased by +16.98% | 0.58 Increased by +6.90% |
| Apr 24, 24 | 0.56 Increased by +19.15% | 0.51 Increased by +9.80% |
| Jan 31, 24 | 0.55 Increased by +12.24% | 0.51 Increased by +7.84% |
| Oct 26, 23 | 0.50 Increased by +16.28% | 0.48 Increased by +4.17% |
| Jul 27, 23 | 0.53 Increased by +20.45% | 0.49 Increased by +8.16% |
| Apr 26, 23 | 0.47 Increased by +20.51% | 0.44 Increased by +6.82% |
| Feb 1, 23 | 0.49 Increased by +8.89% | 0.47 Increased by +4.26% |
| Oct 26, 22 | 0.43 Increased by +4.88% | 0.44 Decreased by -2.27% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 3.53 B Increased by +11.26% | 504.00 M Increased by +168.09% | Increased by +14.29% Increased by +140.95% |
| Jun 30, 23 | 3.60 B Increased by +10.94% | 270.00 M Increased by +3.85% | Increased by +7.50% Decreased by -6.40% |
| Mar 31, 23 | 3.39 B Increased by +12.00% | 314.00 M Increased by +185.45% | Increased by +9.27% Increased by +154.88% |
| Dec 31, 22 | 3.24 B Increased by +3.68% | 140.00 M Increased by +48.94% | Increased by +4.32% Increased by +43.65% |
| Sep 30, 22 | 3.17 B Increased by +8.12% | 188.00 M Decreased by -55.13% | Increased by +5.93% Decreased by -58.50% |
| Jun 30, 22 | 3.24 B Increased by +5.43% | 260.00 M Increased by +39.78% | Increased by +8.01% Increased by +32.59% |
| Mar 31, 22 | 3.03 B Increased by +9.96% | 110.00 M Decreased by -67.74% | Increased by +3.64% Decreased by -70.66% |
| Dec 31, 21 | 3.13 B Increased by +15.47% | 94.00 M Decreased by -38.16% | Increased by +3.01% Decreased by -46.44% |